Guaranteed Protein Knockout for Any Human-Derived Cell Types Using a Novel Multi-guide Strategy. The Best CRISPR Editing Results in Every Cell Type.
Introducing the first and only single-cell multi-omic platform capable of detecting SNVs, CNVs, and protein changes simultaneously from the same cell. Gain a true multi-omic picture from genotype to phenotype for your critical cancer research.
When you study or treat cancer, you don’t want to miss a single cell. Any cell that remains after treatment can lead to relapse. Mission Bio’s Tapestri ®Platform is the only technology that provides single-cell targeted DNA sequencing at single-base resolution.
We understand the blood, sweat and tears of your research. Focus on your research and put other burdens on us.
We help you to use your research funding wisely. No markup and no hidden cost from us.
You control the delivery speed. Priority shipment speeds up your research.
top notch service
No more meaningless waiting. We are responsive to your every request.
Every bit of the research funding counts. We stick with our “no markup” strategy which enables our customers to purchase at the same USD list price as if you were in the United States.
Logistics cost depends on budget and urgency, while urgency depends on experiment progress. You will have the options to choose the matching delivery speed at transparent cost.
Top notch service
Our customer focus approach aims to ease your research work by putting the unnecessary operational burden on us. Experience our incomparable top-notch service quality now.
Latest From Our Blog
A step-by-step guide to CRISPR knockouts CRISPR has ignited a revolution. Although it’s a relatively recent discovery in the history of biotechnology, CRISPR has quickly become a standard laboratory tool and cell engineering is transforming research. One of the most...
What are Immune Checkpoints? Immune checkpoints are regulators of the immune system which prevent the immune system from attacking self-antigens indiscriminately. While this is critical to preventing auto-immune disease it also causes the immune system to be...
Prophylactic treatment with antagonistic anti-TNFα antibodies may improve outcomes of anti-PD-1 and anti-CTLA-4 combination cancer immunotherapy
The combination of anti-PD-1 and anti-CTLA-4 antibody-mediated immunotherapy is remarkably effective against melanoma, renal cell carcinoma, and non-small-cell lung cancer. However, this comes at the cost of frequent, serious immune-related adverse events. Colitis is...
Phone: +852 5744 0607
Fax: +852 3013 9564